{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:42:25Z","timestamp":1777934545045,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cetuximab, an anti-EGFR monoclonal antibody, often cause skin toxicity, most commonly acneiform rash. We present a rare case of glomerulonephritis associated with cetuximab therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Report<\/jats:title>\n                    <jats:p>A 58-year-old male patient recently completed cetuximab-based chemotherapy for metastatic colorectal adenocarcinoma. He presented with acute renal failure, anasarca edema and nephrotic proteinuria. The amount of protein in the 24-h urine test was over 15.6 grams.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management &amp; Outcome<\/jats:title>\n                    <jats:p>The patient showed a dramatic improvement in renal function shortly after terminated of cetuximab therapy without immunosuppressive therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Therefore, drugs targeting epidermal growth factor receptor (EGFR) monoclonal antibody were thought to trigger nephrotic syndrome by causing glomerular damage. As a result, physicians using EGFR monoclonal inhibitors should be very careful about renal functions and proteinuria in patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552211073790","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T08:14:55Z","timestamp":1642061695000},"page":"998-1002","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Nephrotic syndrome induced by cetuximab in a patient with metastatic colorectal cancer"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0926-6748","authenticated-orcid":false,"given":"Mustafa","family":"Korkmaz","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6970-4733","authenticated-orcid":false,"given":"Engin","family":"Hendem","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2597-5931","authenticated-orcid":false,"given":"Melek","family":"Karakurt Ery\u0131lmaz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aykut","family":"Demirk\u0131ran","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4533-0620","authenticated-orcid":false,"given":"Mustafa","family":"Karaa\u011fa\u00e7","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2335-3354","authenticated-orcid":false,"given":"Mehmet","family":"Arta\u00e7","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"key":"bibr1-10781552211073790","unstructured":"Clark JW, Sanoff HK. Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach, https:\/\/www.uptodate.com\/contents\/systemic-therapy-for-nonoperable-metastatic-colorectal-cancer-selecting-the-initial-therapeutic-approach\/ (accessed 26 December 2020)."},{"key":"bibr2-10781552211073790","first-page":"994","volume":"8","author":"Prewett MC","year":"2002","journal-title":"Clin Cancer Res"},{"key":"bibr3-10781552211073790","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0804385"},{"key":"bibr4-10781552211073790","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767170-00008"},{"key":"bibr5-10781552211073790","first-page":"7964015","volume":"2017","author":"Manthri S","year":"2017","journal-title":"Case Rep Nephrol"},{"key":"bibr6-10781552211073790","doi-asserted-by":"publisher","DOI":"10.1177\/1078155212459668"},{"key":"bibr7-10781552211073790","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.01.008"},{"key":"bibr8-10781552211073790","doi-asserted-by":"publisher","DOI":"10.5414\/CN108901"},{"key":"bibr9-10781552211073790","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.09.011"},{"key":"bibr10-10781552211073790","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-015-1216-x"},{"key":"bibr11-10781552211073790","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7080225"},{"key":"bibr12-10781552211073790","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/16.suppl_6.13"},{"key":"bibr13-10781552211073790","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2010.09.011"},{"key":"bibr14-10781552211073790","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2016.09.055"},{"key":"bibr15-10781552211073790","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(05)70541-1"},{"key":"bibr16-10781552211073790","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03446.x"},{"key":"bibr17-10781552211073790","doi-asserted-by":"publisher","DOI":"10.1159\/000321011"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211073790","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552211073790","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211073790","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:26:01Z","timestamp":1777688761000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552211073790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1177\/10781552211073790"],"URL":"https:\/\/doi.org\/10.1177\/10781552211073790","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,13]]}}}